DiCE Molecules is Drug Discovery in United States that focus on monoclonal antibodies business. Founded in 2013. They cover business area such as developer, innovative medicine, immunology, patient, complex disease, treatment, injectable protein-base drug, monoclonal antibody, injection, infusion, convenient oral medicine, serious medical condition.
2013
( 11 years old in 2024 )
Monoclonal Antibodies
-
279 East Grand Avenue
Suite 300, Lobby B
South San Francisco, CA 94080
United States
Private
developerinnovative medicineimmunologypatientcomplex diseasetreatmentinjectable protein-base drugmonoclonal antibodyinjectioninfusionconvenient oral medicineserious medical condition
* We use standard office opening hours in near DiCE Molecules's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
DiCE Molecules is Drug Discovery business from United States that founded in 2013 (11 years old in 2024), DiCE Molecules business is focusing on Monoclonal Antibodies.
DiCE Molecules headquarter office and corporate office address is located in 279 East Grand Avenue Suite 300, Lobby B South San Francisco, CA 94080 United States.
DiCE Molecules was founded in United States.
In 2024, DiCE Molecules is currently focus on monoclonal antibodies sector.
Above is snippet of Google Trends for "monoclonal antibodies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with DiCE Molecules, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
